Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?

Introduction The impact of neoadjuvant therapy on postpancreatectomy complications is inadequately described. Methods Data from the NSQIP Pancreatectomy Demonstration Project (11/2011 to 12/2012) was used to identify patients with pancreatic adenocarcinoma who did and did not receive neoadjuvant therapy. Neoadjuvant therapy was classified as chemotherapy alone or radiation +/- chemotherapy. Outcomes in the neoadjuvant vs. surgery first groups were compared. Results Of 1,562 patients identified at 43 hospitals, 199 (12.7 %) received neoadjuvant therapy (99 chemotherapy alone and 100 radiation +/- chemotherapy). Preoperative biliary stenting (57.9 vs. 44.7 %, p=0.0005), vascular resection (41.5 vs. 17.3 %, p < 0.0001), and open resections (94.0 vs. 91.4 %, p=0.008) were more common in the neoadjuvant group. Thirty-day mortality (2.0 vs. 1.5 %, p=0.56) and postoperative morbidity rates (56.3 vs. 52.8 %, p=0.35) were similar between groups. Neoadjuvant therapy patients had fewer organ space infections (3.0 vs. 10.3 %, p=0.001), and neoadjuvant radiation patients had fewer pancreatic fistulas (7.3 vs. 15.4 %, p=0.03). Conclusions Despite evidence for more extensive disease, patients receiving neoadjuvant therapy did not experience more complications. Neoadjuvant radiation was associated with lower pancreatic fistula rates. These data provide evidence against higher postoperative complication rates in patients with pancreatic cancer who are treated with neoadjuvant therapy.